TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15362251
Drug: Estrogen and
Normalized name: Conjugated estrogen and norgestrel only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen and progesterone therapy
Study: 15362251
Drug: Thyroid therapy
Normalized name: THYROID THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid therapy
Study: 9137847
Drug: Divalproex sodium
Normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex sodium 500 mg
Study: 9137847
Drug: Divalproex sodium
Normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex sodium 1000 mg
Study: 9137847
Drug: Divalproex sodium
Normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex sodium 1500 mg
Study: 3137036
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg pefloxacin b.i.d.
Study: 3137036
Drug: 160/800 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160/800 mg cotrimoxazole b.i.d.
Study: 18461609
Drug: Adefovir/lamivudine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adefovir/lamivudine combination therapy
Study: 29443767
Drug: Oxycodone hydrochloride
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone hydrochloride 0.5 mg/kg + flurbiprofen axetil 150 mg
Study: 29443767
Drug: Oxycodone hydrochloride
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone hydrochloride 0.75 mg/kg + flurbiprofen axetil 150 mg
Study: 29443767
Drug: Oxycodone hydrochloride
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone hydrochloride 1.0 mg/kg + flurbiprofen axetil 150 mg
Study: 26714442
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 1 mcg/kg (Group L)
Study: 26714442
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 2 mcg/kg (Group H)
Study: 26714442
Drug: Second oral
Normalized name: 60 Second Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second oral dose chloral hydrate 25 mg/kg (Group C)
Study: 18707985
Drug: High-bolus dose
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-bolus dose tirofiban (n=491)
Study: 16372826
Drug: Prulifloxacin 600mg
Normalized name: Orbifloxacin
DrugBank: Prulifloxacin (DB11892)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prulifloxacin 600mg administered orally
Study: 11260412
Drug: Cyclosporine plus
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine plus low-dose prednisone
Study: 3935120
Drug: Glibenclamide (2.5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (2.5-10 mg daily)
Study: 3935120
Drug: Chlorpropamide (125-500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpropamide (125-500 mg daily)
Study: 29590326
Drug: Zoster Vaccine
Normalized name: ZOSTER VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoster Vaccine Live (ZV)
Study: 26110349
Drug: Beta-Alanine (BA)
Normalized name: beta-alanine
DrugBank: beta-Alanine (DB03107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-Alanine (BA) supplementation (800 mg + 8 g dextrose)
Study: 26110349
Drug: Placebo (PLA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA) (8 g dextrose)
Study: 24650125
Drug: Multimodal analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal analgesia (dexamethasone, gabapentin, ibuprofen, paracetamol)
Study: 24650125
Drug: Traditional morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional morphine and paracetamol regimen
Study: 22288671
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (dipyrone 600 mg, isometheptene 60 mg, caffeine 60 mg)
Study: 15818745
Drug: Morphine associated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine associated with GTN
Study: 15818745
Drug: Morphine associated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine associated with ISDN
Study: 15818745
Drug: Morphine associated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine associated with PTN
Study: 12421266
Drug: Schedule A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule A: one dose at 0, 1, and 6 months
Study: 12421266
Drug: Schedule B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule B: one dose at 0, 10, and 21 days
Study: 2593767
Drug: Dexamethasone (DEX)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEX) administered intravenously
Study: 2593767
Drug: Saline administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline administered intravenously
Study: 29695772
Drug: Self-monitoring device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-monitoring device for daily salt intake
Study: 28545917
Drug: RYGB patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RYGB patients receiving oral antibiotics
Study: 28545917
Drug: Controls receiving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controls receiving oral antibiotics
Study: 24091318
Drug: Standard fortification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard fortification (3 g/kg/d)
Study: 24091318
Drug: Moderate fortification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate fortification (3.3 g/kg/d)
Study: 24091318
Drug: Aggressive fortification
Normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive fortification (3.6 g/kg/d)
Study: 18248158
Drug: Active laser
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active laser therapy (LLLT)
Study: 11012498
Drug: Intrathecal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal fentanyl 25 microg and ropivacaine 2.5 mg
Study: 11012498
Drug: Intrathecal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal fentanyl 25 microg and bupivacaine 2.5 mg
Study: 8994314
Drug: Combined hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined hepatitis A and B vaccine (3 doses of 1 ml each, containing at least 720 ELISA Units of HAV antigen and 20 micrograms of recombinant HBsAg, administered at 0, 1, and 6 months)
Study: 1427652
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with lymphoblastoid interferon-alpha and levamisole (150 mg three times per week)
Study: 1427652
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with lymphoblastoid interferon-alpha and levamisole
Study: 3880877
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 gel administered intracervically
Study: 3880877
Drug: Demoxytocin buccal
Normalized name: demoxytocin
DrugBank: Demoxytocin (DB13798)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demoxytocin buccal tablets
Study: 31135822
Drug: Accelerated approval
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated approval drugs pending confirmatory data
Study: 31135822
Drug: Drugs with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs with regular approval
Study: 25461793
Drug: Work-related cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Work-related cognitive-behavioral therapy (WCBT) plus vocational services as usual (VSAU)
Study: 25461793
Drug: Work-related cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Work-related cognitive-behavioral therapy (WCBT)
Study: 21034483
Drug: Integrative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative care pathway involving exercise, massage, acupuncture, and cognitive behavioral therapy.
Study: 15803929
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide (IVCY)
Study: 15803929
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose IVCY induction followed by AZA maintenance
Study: 15803929
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose IVCY induction followed by AZA maintenance
Study: 15803929
Drug: Short-term oral
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term oral CY induction followed by AZA maintenance
Study: 12160098
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose of alcohol (0.62 g/kg)
Study: 667244
Drug: Chlordiazepoxide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlordiazepoxide (10 mg and 20 mg)
Study: 667244
Drug: Caffeine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (150 mg and 300 mg)
Study: 667244
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and 'no-drug' treatment
Study: 18927148
Drug: Home oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home oxygen therapy with support from 'hospital in the home' (HiTH)
Study: 14999696
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) at a dose of 13 to 15 mg/kg/d for 2 years
Study: 9260729
Drug: Aptiganel hydrochloride
Normalized name: Chlorpromazine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aptiganel hydrochloride (CNS 1102) infused over 4 hours at doses of 15, 32, 50, or 73 microg/kg
Study: 9260729
Drug: Aptiganel hydrochloride
Normalized name: Chlorpromazine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aptiganel hydrochloride (CNS 1102) at total doses of 32 microg/kg
Study: 9260729
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of Aptiganel hydrochloride (CNS 1102)
Study: 9260729
Drug: Aptiganel hydrochloride
Normalized name: Chlorpromazine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aptiganel hydrochloride (CNS 1102) at total doses of up to 32 microg/kg infused over 4 hours
Study: 3481040
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HDMTX) 1000 mg/m2 iv over 24 hours weekly for 3 weeks, then every 6 weeks for 72 weeks, combined with low-dose 6-mercaptopurine (6MP; 50 mg/m2 orally per day) and methotrexate (MTX; 25 mg/m2 orally per week)
Study: 24665163
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (ALA) 300mg orally once daily for 3 months
Study: 12605586
Drug: Glutamine supplementation
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine supplementation (0.56 g x day(‐1) x kg(‐1))
Study: 10952476
Drug: MS Contin
Normalized name: MS Contin
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MS Contin tablets (MSC)
Study: 10952476
Drug: Controlled-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release morphine sulphate suppository (MSR)
Study: 8975964
Drug: α-interferon treatment
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-interferon treatment
Study: 1547765
Drug: Nifedipine (NFD)
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine (NFD) 20 mg b.i.d. for 4 weeks
Study: 1547765
Drug: Nifedipine (NFD)
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine (NFD) 40 mg b.i.d. for 4 weeks
Study: 3113957
Drug: Metoprolol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol plus intravenous nitroglycerin (Group 2)
Study: 28933582
Drug: Systane® Ultra
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systane® Ultra treatments
Study: 24993741
Drug: Triple eradication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple eradication treatment for H. pylori
Study: 16847013
Drug: Immediate antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate antibiotics (chloramphenicol eye drops; n = 104)
Study: 16847013
Drug: Delayed antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed antibiotics (n = 109)
Study: 16847013
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics (controls; n = 94)
Study: 16847013
Drug: Immediate antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate antibiotics (n = 104)
Study: 15193674
Drug: Verapamil 240
Normalized name: verapamil 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 240 mg twice daily for six months
Study: 10960931
Drug: 5-FU and
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU and its modulation (specific agent, dose, and route not detailed)
Study: 9316554
Drug: High-dose hepatitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose hepatitis B vaccine (40 micrograms at 0, 1, 2, and 6 months)
Study: 9316554
Drug: Standard-dose hepatitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose hepatitis B vaccine (20 micrograms at 0.1, and 6 months)
Study: 8403467
Drug: Topical n‐6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical n‐6 essential fatty acids (evening primrose oil) added to 0.1% betamethasone valerate
Study: 8403467
Drug: 0.1% betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% betamethasone valerate twice daily for 3 weeks
Study: 3744133
Drug: Intravenous unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous unfractionated heparin (UFH) 240 anti‐Xa U/kg/12 h
Study: 3744133
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin Fragmin 240 anti‐Xa U/kg/12 h
Study: 3744133
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin Fragmin 120 anti‐Xa U/kg/12 h
Study: 3744133
Drug: Subcutaneous Fragmin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Fragmin 120 anti‐Xa U/kg 2 times daily
Study: 26947719
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (up to 300 units), administered subcutaneously, two injections 12 weeks apart.
Study: 26947719
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered subcutaneously, two injections 12 weeks apart.
Study: 18507107
Drug: suspension-emulsion
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: suspension-emulsion
Study: 12816878
Drug: 4 egg
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 egg yolks daily
Study: 12816878
Drug: 2 egg
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 egg yolks daily
Study: 10360660
Drug: Paclitaxel 135
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 135 mg m(‐2) by 24‐h intravenous infusion + cisplatin
Study: 10360660
Drug: Paclitaxel 250
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 250 mg m(‐2) by 24‐h intravenous infusion + cisplatin + granulocyte colony‐stimulating factor (G‐CSF)
Study: 10360660
Drug: Paclitaxel 135
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 135 mg m(‐2) + cisplatin administered as an outpatient by 3‐h infusion
Study: 7741793
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen (E2) substitution (4 mg)
Study: 2126836
Drug: Erdosteine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdosteine (300 mg 3 times daily for 2 weeks)
Study: 27064975
Drug: IM20 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM20 × 3 (3 intramuscular standard-dose injections of 20-μg at weeks 0, 4, and 24)
Study: 27064975
Drug: IM40 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM40 × 4 (4 intramuscular double-dose injections of 40-μg at weeks 0, 4, 8, and 24)
Study: 27064975
Drug: ID4 ×
Normalized name: Idarubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: ID4 × 4 (4 intradermal low-dose injections of 4-μg at weeks 0, 4, 8, and 24)
Study: 20584070
Drug: telmisartan at
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: telmisartan at 80 mg day(‐1)
Study: 20584070
Drug: enalapril at
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril at 10 mg day(‐1)
Study: 12401533
Drug: Compliance with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compliance with Step II dietary goals (≤30% of total calories from fat, <7% of calories from saturated fat, daily dietary cholesterol <200 mg)
Study: 12401533
Drug: Consumption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consumption of five or more daily servings of fruits or vegetables
Study: 10099039
Drug: 5.0 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg/d isradipine
Study: 10099039
Drug: 7.5 mg/d
Normalized name: Arixtra 7.5 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg/d isradipine
Study: 10099039
Drug: 10.0 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.0 mg/d isradipine
Study: 22315014
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss therapy
Study: 20049572
Drug: Continuous intraarticular
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intraarticular infusion with 300 mL ropivacaine 0.2% at a speed of 5 mL/hour
Study: 20049572
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution at an infusion speed of 5 mL/hour (Control)
Study: 12508961
Drug: Doxazosin (2-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (2-4 mg/day)
Study: 1659975
Drug: Temafloxacin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temafloxacin (600 mg)
Study: 6790805
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of nitroglycerin
Study: 28742505
Drug: Hops dry
Normalized name: HOPS
DrugBank: Hops (DB10687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hops dry extract (Melcalin hops); 0.2 gr capsules once daily for 4 weeks
Study: 28742505
Drug: Placebo; 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo; 0.2 gr capsules once daily for 4 weeks
Study: 16680561
Drug: Desipramine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (50 mg) alone
Study: 16680561
Drug: Desipramine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (50 mg) with cinacalcet (90 mg for 7 days)
Study: 9440757
Drug: 5-FU continuous
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU continuous intravenous infusion (CI)
Study: 9440757
Drug: 5-FU bolus
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU bolus administration
Study: 7787380
Drug: Pre‐retirement programmes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐retirement programmes including transition and choice‐making skills; no specific dosage or duration mentioned.
Study: 1969290
Drug: Fentanyl administered
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl administered i.v. before propofol infusion
Study: 29909704
Drug: Ringer's solution
Normalized name: Ringer's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's solution plus oral fluids
Study: 29909704
Drug: Dextrose solution
Normalized name: Dextrose solution
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose solution 5% plus oral fluids
Study: 29909704
Drug: Oral fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluids alone
Study: 24314359
Drug: TAK-085 2
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-085 2 g (2 g once daily)
Study: 24314359
Drug: TAK-085 4
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-085 4 g (2 g twice daily)
Study: 24314359
Drug: EPA-E 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA-E 1.8 g (0.6 g three times daily)
Study: 24314359
Drug: TAK-085 2
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-085 2 g
Study: 24314359
Drug: TAK-085 4
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-085 4 g
Study: 24314359
Drug: EPA-E 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA-E 1.8 g
Study: 17370494
Drug: O3 acupoint
Normalized name: O3-Methylmorphine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: O3 acupoint injection (30 microg/mL)
Study: 17370494
Drug: Danggui point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danggui point injection
Study: 15049986
Drug: Doxazosin 1-8
Normalized name: doxazosin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 1-8 mg once daily
Study: 15049986
Drug: Alfuzosin 5-10
Normalized name: alfuzosin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin 5-10 mg divided in two or three daily doses
Study: 11269737
Drug: 5-FU (370
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU (370 mg/m2 i.v. over 1 h, days 2-6)
Study: 9517642
Drug: Nizatidine 300
Normalized name: nizatidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 300 mg at night for 2 weeks
Study: 2652864
Drug: Ketoconazole high
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole high dose (H.D.)